Evidence map›Paper›PMID 38664855›Full record

ArticleVirology journal2024

Antiviral screening of natural, anti-inflammatory compound library against African swine fever virus.

Joshua A Jackman, Astghik Hakobyan, Rafayela Grigoryan, Roza Izmailyan, Charles C Elrod, Hovakim Zakaryan

Open access · goldAbstract read
In one paragraph

Article in Virology journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
6.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Joshua A JackmanSchool of Chemical Engineering and Translational Nanobioscience Research Center, Sungkyunkwan University, Suwon, 16419, Republic of Korea. jjackman@skku.edu.
Astghik HakobyanLaboratory of Antiviral Drug Discovery, Institute of Molecular Biology of NAS, Yerevan, Armenia.
Rafayela GrigoryanLaboratory of Antiviral Drug Discovery, Institute of Molecular Biology of NAS, Yerevan, Armenia.
Roza IzmailyanLaboratory of Antiviral Drug Discovery, Institute of Molecular Biology of NAS, Yerevan, Armenia.
Charles C Elrod *Natural Biologics Inc, Newfield, NY, 14867, USA. cce1@cornell.edu.
Hovakim Zakaryan *Laboratory of Antiviral Drug Discovery, Institute of Molecular Biology of NAS, Yerevan, Armenia. h_zakaryan@mb.sci.am.
Institute of Molecular Biology · AMBiolog (United States) · USSungkyunkwan University · KR

Funding

National Research Foundation of Korea 2020R1C1C1004385
6 · The paper itself

Abstract

backgroundAfrican swine fever virus (ASFV) is a major threat to pig production and the lack of effective vaccines underscores the need to develop robust antiviral countermeasures. Pathologically, a significant elevation in pro-inflammatory cytokine production is associated with ASFV infection in pigs and there is high interest in identifying dual-acting natural compounds that exhibit antiviral and anti-inflammatory activities.

methodsUsing the laboratory-adapted ASFV BA71V strain, we screened a library of 297 natural, anti-inflammatory compounds to identify promising candidates that protected Vero cells against virus-induced cytopathic effect (CPE). Virus yield reduction, virucidal, and cell cytotoxicity experiments were performed on positive hits and two lead compounds were further characterized in dose-dependent assays along with time-of-addition, time-of-removal, virus entry, and viral protein synthesis assays. The antiviral effects of the two lead compounds on mitigating virulent ASFV infection in porcine macrophages (PAMs) were also tested using similar methods, and the ability to inhibit pro-inflammatory cytokine production during virulent ASFV infection was assessed by enzyme-linked immunosorbent assay (ELISA).

resultsThe screen identified five compounds that inhibited ASFV-induced CPE by greater than 50% and virus yield reduction experiments showed that two of these compounds, tetrandrine and berbamine, exhibited particularly high levels of anti-ASFV activity. Mechanistic analysis confirmed that both compounds potently inhibited early stages of ASFV infection and that the compounds also inhibited infection of PAMs by the virulent ASFV Arm/07 isolate. Importantly, during ASFV infection in PAM cells, both compounds markedly reduced the production of pro-inflammatory cytokines involved in disease pathogenesis while tetrandrine had a greater and more sustained anti-inflammatory effect than berbamine.

conclusionsTogether, these findings support that dual-acting natural compounds with antiviral and anti-inflammatory properties hold promise as preventative and therapeutic agents to combat ASFV infection by simultaneously inhibiting viral replication and reducing virus-induced cytokine production.

Indexed as

African Swine Fever VirusAnti-Inflammatory AgentsAntiviral AgentsAfrican Swine FeverAnimalsBiological ProductsChlorocebus aethiopsCytokinesCytopathogenic Effect, ViralDrug Evaluation, PreclinicalMacrophagesSwineVero CellsVirus InternalizationVirus ReplicationAnti-Inflammatory AgentsAntiviral AgentsBiological ProductsCytokinesAfrican swine fever virusAnti-inflammatoryAntiviralCytokine productionScreening

Identifiers

PMID38664855
PMCPMC11046949
OpenAlexW4395466795

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.